ClinicalTrials.gg
RecruitingNCT07398417FORWARDUpdated Nov 10, 2026

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

A Phase 3 interventional study of AXS-14 (Esreboxetine) and Placebo in Fibromyalgia, sponsored by Axsome Therapeutics, Inc.. Recruiting at 57 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 10, 20265 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Planned enrollment
16th of 320
620 · median 72
Started
2026
with 19 others
Phase 3
55 of 369
2 open now
Primary completion
2028-03
later than 44 of 62 live
Registered
357th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 16th largest by planned enrollment of the 320 interventional ones that give a count, is one of 20 that started in 2026, is one of 55 in phase 3, reaches primary completion later than 44 of the 62 other live ones, and was the 357th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

Read the detailed description

This study is a multi-center trial consisting of a 12-week open-label treatment period (OLP), followed by a 12-week double-blind, placebo-controlled, randomized withdrawal period (DBRWP). During the OLP, subjects receive open-label AXS-14. Subjects achieving treatment response will be randomized into the DBRWP in a 1:1 ratio to either continue on AXS-14 or switch to placebo for up to 12 weeks or until a loss of therapeutic response occurs.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Fibromyalgia
  • Central Sensitization
  • Allodynia
  • Hyperalgesia
  • Hypersensitivity to sensory stimuli
  • Inhibitor of the norepinephrine transporter (NET)
  • Esreboxetine
  • AXS-14
  • Axsome
  • Norepinephrine reuptake inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a primary diagnosis of fibromyalgia based on the 2016 ACR diagnostic criteria.
  • Male or female, ≥18 years of age.
  • Provides written to participate in the study before conducting any study procedures.

Exclusion criteria

Exclusion Criteria:

  • Previous participation in a clinical trial with reboxetine or esreboxetine or currently receiving treatment with reboxetine for any condition.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    AXS-14 (esreboxetine)

    * Up to 12 weeks in the open-label period; * Up to 12 weeks in the randomized double-blind period (if applicable)

    Drug: AXS-14 (Esreboxetine)

  • Placebo comparator
    Placebo

    • Up to 12 weeks in the randomized double-blind period (if applicable)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time from randomization to loss of therapeutic response

    Time frame: 12 Weeks

07

Study locations

57 of 57 sites recruiting
  • Clinical Research Site
    Glendale, Arizona 85308, United States
    Recruiting
  • Clinical Research Site
    Phoenix, Arizona 85032, United States
    Recruiting
  • Clinical Research Site
    Tucson, Arizona 85704, United States
    Recruiting
  • Clinical Research Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Clinical Research Site
    Anaheim, California 92801, United States
    Recruiting
  • Clinical Research Site
    Oceanside, California 92056, United States
    Recruiting
  • Clinical Research Site
    Redlands, California 92374, United States
    Recruiting
  • Clinical Research Site
    Sacramento, California 95821, United States
    Recruiting
  • Clinical Research Site
    Santa Ana, California 92705, United States
    Recruiting
  • Clinical Research Site
    Cromwell, Connecticut 06416, United States
    Recruiting
  • Clinical Research Site
    Hollywood, Florida 33021, United States
    Recruiting
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Clinical Research Site
    Lakeland, Florida 33803, United States
    Recruiting
  • Clinical Research Site
    Maitland, Florida 32751, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32801, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32832, United States
    Recruiting
  • Clinical Research Site
    Tampa, Florida 33634, United States
    Recruiting
  • Clinical Research Site
    The Villages, Florida 32159, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia 30328, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia 30329, United States
    Recruiting
  • Clinical Research Site
    Marietta, Georgia 30060, United States
    Recruiting
  • Clinical Research Site
    Norcross, Georgia 30092, United States
    Recruiting
  • Clinical Research Site
    Chicago, Illinois 60634, United States
    Recruiting
  • Clinical Research Site
    Tinley Park, Illinois 60477, United States
    Recruiting
  • Clinical Research Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Clinical Research Site
    Overland Park, Kansas 66209, United States
    Recruiting
  • Clinical Research Site
    Overland Park, Kansas 66212, United States
    Recruiting
  • Clinical Research Site
    Louisville, Kentucky 40205, United States
    Recruiting
  • Clinical Research Site
    Prairieville, Louisiana 70769, United States
    Recruiting
  • Clinical Research Site
    Rockville, Maryland 20850, United States
    Recruiting
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
    Recruiting
  • Clinical Research Site
    North Dartmouth, Massachusetts 02747, United States
    Recruiting
  • Clinical Research Site
    Watertown, Massachusetts 02472, United States
    Recruiting
  • Clinical Research Site
    Hazelwood, Missouri 63042, United States
    Recruiting
  • Clinical Research Site
    Springfield, Missouri 65807, United States
    Recruiting
  • Clinical Research Site
    Town and Country, Missouri 63017, United States
    Recruiting
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
    Recruiting
  • Clinical Research Site
    Brooklyn, New York 11235, United States
    Recruiting
  • Clinical Research Site
    Hartsdale, New York 10530, United States
    Recruiting
  • Clinical Research Site
    Williamsville, New York 14221, United States
    Recruiting
  • Clinical Research Site
    High Point, North Carolina 27260, United States
    Recruiting
  • Clinical Research Site
    Huber Heights, Ohio 45424, United States
    Recruiting
  • Clinical Research Site
    Milford, Ohio 45150, United States
    Recruiting
  • Clinical Research Site
    Tulsa, Oklahoma 74133, United States
    Recruiting
  • Clinical Research Site
    Duncansville, Pennsylvania 16635, United States
    Recruiting
  • Clinical Research Site
    Plymouth Meeting, Pennsylvania 19462, United States
    Recruiting
  • Clinical Research Site
    Cranston, Rhode Island 02920, United States
    Recruiting
  • Clinical Research Site
    Charleston, South Carolina 29407, United States
    Recruiting
  • Clinical Research Site
    Knoxville, Tennessee 37909, United States
    Recruiting
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
    Recruiting
  • Clinical Research Site
    Austin, Texas 78731, United States
    Recruiting
  • Clinical Research Site
    Austin, Texas 78737, United States
    Recruiting
  • Clinical Research Site
    Dallas, Texas 75251, United States
    Recruiting
  • Clinical Research Site
    Houston, Texas 77089, United States
    Recruiting
  • Clinical Research Site
    Prosper, Texas 75078, United States
    Recruiting
  • Clinical Research Site
    San Antonio, Texas 78240, United States
    Recruiting
  • Clinical Research Site
    The Woodlands, Texas 77832, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 9, 2026
StartActual
Jan 14, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed
Show 5 added (5 United States)
  • Clinical Research Site · Rockville, United States
  • Clinical Research Site · North Dartmouth, United States
  • Clinical Research Site · High Point, United States
  • Clinical Research Site · Plymouth Meeting, United States
  • Clinical Research Site · Charleston, United States
Show 1 removed
  • Houston · High Point, United States
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    5 sites added, 1 site removed
    Show 5 added (5 United States)
    • Clinical Research Site · Rockville, United States
    • Clinical Research Site · North Dartmouth, United States
    • Clinical Research Site · High Point, United States
    • Clinical Research Site · Plymouth Meeting, United States
    • Clinical Research Site · Charleston, United States
    Show 1 removed
    • Houston · High Point, United States
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07398417
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jan 14, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Study Director
Contact
AXS-14-FM-301@axsome.com
212-332-5061

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esreboxetine

Start the discussion